HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary-Reference-Cited by-同舟云学术

HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary

Published:2018-07 Issue:7 Volume:14 Page:437-441
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Wolff Antonio C.¹,Hammond M. Elizabeth Hale¹,Allison Kimberly H.¹,Harvey Brittany E.¹,McShane Lisa M.¹,Dowsett Mitchell¹

Affiliation:

1. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City, UT; Stanford University School of Medicine, Stanford, CA; American Society of Clinical Oncology, Alexandria, VA; National Cancer Institute, Bethesda, MD; and The Royal Marsden NHS Foundation Trust, London, United Kingdom

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology(nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.18.00206

Reference15 articles.

1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

2. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

3. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

4. Fehrenbacher L CR, Geyer CE, Rastogi P, et al: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). San Antonio Breast Cancer Symposium 2017, San Antonio, TX, December 5-9, 2017 (abstr GS1-02)

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas;Cancers;2024-09-13

2. Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice;Pathology and Oncology Research;2024-08-29

3. Preoperative prediction of nodal status using clinical data and artificial intelligence derived mammogram features enabling abstention of sentinel lymph node biopsy in breast cancer;Frontiers in Oncology;2024-07-10

4. Plasma Metabolome Signatures to Predict Responsiveness to Neoadjuvant Chemotherapy in Breast Cancer;Cancers;2024-07-06

5. Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy;European Journal of Nuclear Medicine and Molecular Imaging;2024-06-26